Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06891560

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-20

34

Participants Needed

7

Research Sites

100 weeks

Total Duration

On this page

Sponsors

M

Memorial Sloan Kettering Cancer Center

Lead Sponsor

A

Astellas Pharma US, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

CONDITIONS

Official Title

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed diagnosis of adenoid cystic carcinoma, including cancers from non-salivary gland primary sites
  • Recurrent and/or metastatic disease not suitable for curative treatment
  • At least 4 weeks since last systemic treatment and 2 weeks since radiotherapy with recovery from related side effects
  • Measurable disease by RECIST V1.1 criteria
  • Evidence of new or worsening tumor or symptoms within 6 months prior to enrollment
  • Age 18 years or older
  • ECOG performance status 0 or 1, or Karnofsky score 70% or higher
  • Availability of tumor tissue for research purposes, or approval by the Investigator if not available
  • Screening lab tests meeting specified blood counts and organ function levels
  • Willingness to sign informed consent
  • Male participants agree to use contraception and avoid sperm donation during treatment and for 4 months after
  • Female participants agree not to donate eggs during the study and for 3 weeks after last dose
  • Female participants must not be pregnant or be of non-childbearing potential, or if childbearing potential, must use effective contraception throughout treatment and 2 months after
Not Eligible

You will not qualify if you...

  • Untreated brain metastases; treated brain metastases must be stable without progression for at least 4 weeks and no steroid use for 14 days prior to treatment
  • Prior malignancy treated within 2 years before study drug start, except certain skin and in situ cancers
  • Systemic anti-cancer therapy within 4 weeks of starting study treatment
  • Grade 2 or higher peripheral neuropathy
  • Dry eyes, keratitis, keratopathy, or active conjunctivitis
  • Significant heart conditions within past 6 months
  • Active infection requiring systemic treatment
  • Known HIV infection or active hepatitis B or C infection
  • History or current pneumonitis or interstitial lung disease requiring steroids
  • Renal failure requiring dialysis
  • Breastfeeding during treatment and for 3 weeks after last dose
  • Any other medical condition or abnormality that could interfere with study participation or results as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, United States, 07920

Actively Recruiting

2

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, United States, 07748

Actively Recruiting

3

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States, 07645

Actively Recruiting

4

Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)

Commack, New York, United States, 11725

Actively Recruiting

5

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, United States, 10604

Actively Recruiting

6

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States, 10065

Actively Recruiting

7

Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale, New York, United States, 11553

Actively Recruiting

Loading map...

Research Team

A

Alan Ho, MD, PhD

CONTACT

W

Winston Wong, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | DecenTrialz